Studies psychotic episodes in children and adolescents with schizophrenia
Studies children and teens with psychosis through interviews, brain scans and genetic tests.
Plain-language title generated from the registry record
Registry title: Dimensional and Developmental Profiles of Psychosis in Children and Adolescents
Key facts
- Where
- Gentilly, Lille, Nice, Paris, and Rouen, FranceSee the 6 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 7 and 20 years old?
Source: NCT04370730, who can take part
Where in France
- Fondation Vallée, GentillyGentilly, FranceNot yet recruiting
- CHRU de LilleLille, FranceNot yet recruiting
- CHU de NiceNice, FranceNot yet recruiting
- Pitié-SalpêtrièreParis, FranceTaking people
- CHU de RouenRouen, FranceNot yet recruiting
- CHU de RouvrayRouen, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT04370730
- Record updated
- 23 January 2026
- Original description
Five collaborating sites in France will study the broad spectrum of schizophrenia in children and adolescents. Patients will be studied with diagnostic interviews, developmental histories, dimensional clinical ratings, comprehensive cognitive assessments, neuroimaging and DNA (copy number variant) analyses (in families and patients who agree), and follow-up of course of illness, cognitive status and treatment response to specific antipsychotic drugs. The goal of the study is to test a prior hypothesis about clinical subgroups in this population and to test whether these subgroups predict antipsychotic medication response.Read full original descriptionShow less
Dimensional and Developmental Approach to Psychotic Episodes in Children and Adolescents: Impact on Clinical Management
Five collaborating sites in France will study the broad spectrum of schizophrenia in children and adolescents. Patients will be studied with diagnostic interviews, developmental histories, dimensional clinical ratings, comprehensive cognitive assessments, neuroimaging and DNA (copy number variant) analyses (in families and patients who agree), and follow-up of course of illness, cognitive status and treatment response to specific antipsychotic drugs. The goal of the study is to test a prior hypothesis about clinical subgroups in this population and to test whether these subgroups predict antipsychotic medication response.
Inclusion: Children and young adults ages 7-20 years with age of onset of psychotic disorder between 7-17 years; Hospitalized or seen for out-patient treatment for a psychotic episode, acute or chronic; DSM-V diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder not otherwise specified, or major depressive episode with psychotic features; Written informed consent signed by the parents or the individual(s) with legal parental authority, and by the minor patient if his/her condition permits; Written informed consent signed by the patient if he/she is a major, after clinical stabilization (not delusional); Has health insurance coverage from Social Security (France) (not AME coverage); Parents : no specific criteria; Siblings : siblings are eligible to participate if there are at least two first-degree relatives with psychotic disorders (including the patient) in the family; Written informed consent for the genetic part of the study signed by any participating parents and siblings; Has health insurance coverage from Social Security (France) (not AME coverage).
Exclusion: Psychoses judged to be secondary to medical illness, medication effects or drugs of abuse; Diagnosis of bipolar disorder; Moderate or severe intellectual deficiency (IQ < 50); Patients who are under legal guardianship; For the neuroimaging part of the study only : any contraindications to Magnetic Resonance Imaging.